Latest Clinical Evidence Presented at APWCA's Wound Week™ 2023 Illustrates the Significant and New Clinical Utility of the MolecuLight Point-of-Care Imaging Platform
The PennZone/10245458

Trending...
TORONTO and PHILADELPHIA, Sept. 21, 2023 ~ MolecuLight Inc., a leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, presented 6 Clinical Posters, a Presentation, and a Hands-On Workshop at the American Professional Wound Care Association's (APWCA) Wound Week™. The event was held from September 20 - 24, 2023 in Philadelphia, PA.

Dr. Thomas Serena, the Founder and Medical Director of The SerenaGroup®, commented on the importance of MolecuLight's point-of-care imaging of bacterial load as an essential tool for all wound care practitioners. He said that the evidence is irrefutable and that it is supported by the results of their 1,447 patient, multi-center study titled "Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging". The use of MolecuLight reduced antibiotic usage by 78%, showing that identifying and characterizing elevated bacterial loads in wounds can help clinicians make more informed decisions and provide the most appropriate treatment.

More on The PennZone
Anil Amlani, MolecuLight's CEO expressed his excitement about the significant additional clinical evidence being presented at Wound Week 2023 showing the impressive results derived from MolecuLight point-of-care devices. He said that these clinical insights span the wound care continuum including wound hygiene, wound bed preparation, antimicrobial stewardship, and patient engagement (through the incorporation of MolecuLight). In addition to these benefits, MolecuLight is helping combat racial inequity by being an imaging technology that elevates the detection of bacteria across all skin tones. Involving MolecuLight in patient care has improved wound healing outcomes as shown by results from a new 12-week randomized controlled trial.

The 6 clinical posters and presentation featuring the MolecuLight i:X at Wound Week 2023 were presented by Dr. Alisha Oropallo (Northwell Comprehensive Wound Healing Center), Dr. Charles Andersen (Vascular/Endovascular/Limb Preservation Surgery Service), and Dr. Thomas Serena (SerenaGroup Research Foundation). These posters included 12-week RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates; Pseudomonas Scrub Down: Advances in Wound Imaging Objectively Confirm the Efficacy of Acetic Acid Against this Pathogen; Bacterial load imaging of chronic wound bacteria supports patient adherence, empowerment and may prevent negative outcomes; Strategies to improve equity in wound bacterial-infection assessments on skin of color; Multimodal imaging device for real-time bacterial load and thermal imaging: a study of synergy in clinical wound assessment workflow; Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging; Co-localization of High Bacterial Load with Regions of Pain in Venous Leg Ulcers: Imaging Informs Interventions and Validates Patient Self-Reported Pain.

More on The PennZone
The Hands-On Skills Workshop was held on Saturday September 23rd from 2:45 pm – 4:45 pm where attendees had an opportunity to experience first hand how to use MolecuLight i:X® and DX™ imaging devices for themselves. They were also available for demonstration at booth #40 located in Exhibit Hall throughout Wound Week 2023.

MolecuLight Inc.'s presence at APWCA's Wound Week™ provided attendees with valuable insights into how their point-of-care fluorescence imaging can be used to detect elevated bacterial loads within wounds which can help clinicians make more informed decisions when providing treatment options to their patients while also helping combat racial inequity through its ability to detect bacteria across all skin tones.
Show All News | Disclaimer | Report Violation

0 Comments

Latest on The PennZone